Soligenix Updates Medical Advisory Board to Advance Phase 3 Development of HyBryte for Cutaneous T-Cell Lymphoma
TL;DR
Soligenix strengthens its competitive position by expanding its Medical Advisory Board to accelerate HyBryte's Phase 3 development and potential commercialization for CTCL treatment.
Soligenix is advancing HyBryte, a photodynamic therapy using synthetic hypericin activated by visible light, through Phase 3 clinical trials for cutaneous T-cell lymphoma treatment.
This development brings hope for improved treatment options for CTCL patients worldwide, potentially enhancing quality of life for those with this rare disease.
Soligenix's novel photodynamic therapy uses synthetic hypericin with visible light, offering a unique approach to treating cutaneous T-cell lymphoma through targeted activation.
Soligenix Inc., a late-stage biopharmaceutical company trading on NASDAQ under the symbol SNGX, has announced updates to its U.S. Medical Advisory Board for cutaneous T-cell lymphoma. This strategic move aims to support the ongoing Phase 3 development of HyBryte, the company's synthetic hypericin photodynamic therapy. The newly expanded board comprises leading dermatologic and oncologic experts who will provide crucial guidance as Soligenix advances both regulatory and commercialization activities for this innovative treatment approach.
Christopher J. Schaber, PhD, President and CEO of Soligenix, emphasized the significance of these additions, stating that the inclusion of new key opinion leaders reinforces the program's clinical depth and demonstrates the company's commitment to bringing HyBryte to CTCL patients worldwide. This enhanced advisory structure comes at a critical juncture in the drug development process, following successful completion of the second Phase 3 study, with regulatory approvals being sought to support potential commercialization across global markets.
The development of HyBryte represents a novel approach to treating cutaneous T-cell lymphoma through photodynamic therapy that utilizes safe visible light. This treatment modality offers potential advantages over existing therapies, particularly in managing this rare form of cancer that affects the skin. The company's Specialized BioTherapeutics business segment is actively moving toward potential commercialization of HyBryte, with the updated Medical Advisory Board playing a pivotal role in shaping the final stages of development and market preparation strategies.
Beyond the CTCL application, Soligenix is exploring expansion opportunities for synthetic hypericin technology into other conditions, including psoriasis under the development code SGX302. The company's broader pipeline includes first-in-class innate defense regulator technology with dusquetide for inflammatory diseases, particularly oral mucositis in head and neck cancer patients, and additional applications in Behcet's Disease. These developments highlight the company's comprehensive approach to addressing unmet medical needs in rare disease treatment.
Soligenix maintains an additional business segment focused on Public Health Solutions, which includes vaccine development programs supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority. The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX. The advancement of HyBryte through Phase 3 development with enhanced expert guidance represents a significant milestone in addressing treatment gaps for CTCL patients and demonstrates the ongoing innovation in photodynamic therapy approaches for dermatologic cancers.
Curated from InvestorBrandNetwork (IBN)